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Gene therapy represents a promising therapeutic option for many inherited and acquired retinal diseases. Recombinant adeno-asso-
ciated viral vectors (AAV) are the most eﬃcient tools to transfer genes in vivo to the retina. The recent identiﬁcation of dozens of novel
AAV serotypes enormously expands on the versatility of AAV as vector system for in vivo somatic gene transfer. The results from the
forthcoming trials with AAV in the retina of patients with Leber Congenital Amaurosis will be critical for the rapid development of
AAV-based therapeutics for retinal diseases.
 2007 Elsevier Ltd. All rights reserved.
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Adeno-associated viruses (AAVs) belong to the Parvo-
viridae family. These non-human pathogens possess a lin-
ear, single-stranded DNA genome that can replicate in
the presence of diﬀerent helper viruses such as adenovirus,
herpes virus or papilloma virus (Muzyczka, 2001). AAVs
were originally isolated as contaminants from laboratory
stocks of adenoviruses.
The AAV genome (4.7 kb) consists of two open reading
frames, rep, required for viral genome replication; and cap,
encoding AAV structural proteins, rep and cap DNA
sequences are enclosed within two symmetric T shaped pal-
indromic terminal sequences called inverted terminal
repeats (ITRs) (Muzyczka, 2001). Recombinant vectors
are generated by deleting the rep and cap sequences from
the genome and by inserting the therapeutic gene of interest
between the ITRs.
AAV vectors are particularly advantageous for gene
transfer because of their ability to transduce non-dividing0042-6989/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
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E-mail address: auricchio@tigem.it (A. Auricchio).cells, and the possibility of a long and sustained levels of
therapeutic gene expression. Since the generation of the
ﬁrst recombinant AAV2 vector (Hermonat & Muzyczka,
1984; Tratschin, West, Sandbank, & Carter, 1984), 108
novel capsid sequences have been isolated (from 55 human
and 53 non-human primates), and some of them were used
to generate novel vectors for gene transfer (Chiorini, Kim,
Yang, & Kotin, 1999; Chiorini, Yang, Liu, Safer, & Kotin,
1997; Gao et al., 2002; Gao et al., 2004; Gao, Vandenber-
ghe, & Wilson, 2005; Rutledge, Halbert, & Russell, 1998;
Xiao et al., 1999). Recombinant vectors can be generated
using both capsid proteins and genomes from the same
serotype or the vector genome can be derived from
AAV2, and included in the capsid from an alternative
AAV serotype (Fig. 1) (Chao et al., 2000; Hildinger
et al., 2001). This allows to assess the net contribution of
the capsid proteins to vector transduction. Exchanging
capsids among various AAV serotypes is eﬀective for con-
ferring speciﬁc cellular tropism and intensity as well as
onset of gene expression (Fig. 1). For example, AAV 2/1
(Gregorevic et al., 2004; Rabinowitz et al., 2002), 2/7
(Gao et al., 2002), 2/8 (Wang et al., 2005) and 2/9 (Inagaki
et al., 2006; Pacak et al., 2006) (where the ﬁrst number
deﬁnes the vector genome and the second the capsid) eﬃ-
ciently transduce muscle and heart by either direct or sys-
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Fig. 1. Generation of recombinant vectors based on diﬀerent AAV serotypes. Transfection in the packaging cells of the plasmids containing: the AAV
genome (with the therapeutic gene contained between the viral inverted terminal repeats, ITRs) and the packaging sequences (the cap genes encoding for
the capsids and the rep open reading frames belonging to serotype 2 to allow the most eﬃcient packaging of a viral genome with AAV2 ITRs) results in
production of recombinant virions. The hybrid virions containing the genome of one serotype (i.e. AAV2) and a diﬀerent capsid (AAV2/1–9) have tropism
dependent on the capsid sequence.
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larly amenable for liver-directed gene transfer (Gao et al.,
2002; Inagaki et al., 2006), while AAV 2/1 (Burger et al.,
2004; Passini et al., 2003), 2/4 (Liu, Martins, Chiorini, &
Davidson, 2005), 2/5 (Burger et al., 2004; Mastakov, Baer,
Kotin, & During, 2002), 2/9 and Rh10 (Cearley & Wolfe,
2006) can transduce diﬀerent cells of the central nervous
system (CNS). In addition, AAV2/6 (Halbert, Allen, &
Miller, 2001), 2/5 (Auricchio, O’Connor, et al., 2002; Zab-
ner et al., 2000) and 2/9 (Limberis & Wilson, 2006) eﬃ-
ciently transfer genes to conducting airway as well as
alveolar cells. Onset of gene expression is also capsid
dependent as vectors with AAV5 or 1 capsids have detect-
able levels of transgene expression within days following
subretinal administration while AAV2/2 vectors require
weeks to achieve the same levels of gene expression (Auric-
chio et al., 2001). The combination of speciﬁcity and eﬃ-
ciency of in vivo gene transfer derived from the use of the
various AAV serotypes has allowed the development of
novel therapeutic options for inherited and acquired
human diseases.
2. Recombinant AAV vectors in the retina
The structure and accessibility of the retina makes it an
ideal target organ for genetic therapies (Allocca, Tessitore,
Cotugno, & Auricchio, 2006; Auricchio & Rolling, 2005;
Bennett & Maguire, 2000). The partial immune privileged
properties of the eye can limit immune responses toward
the transgene and the vector. In addition, the eye is
enclosed and the presence of the blood–retinal-barrier
can help avoiding unintentional spreading of vectors to
neighboring tissues as well as to the general circulation.Retinal diseases are transmitted as monogenic or com-
plex traits. In the last two decades over 130 genes have been
identiﬁed that cause retinal diseases (Retinal Information
Network: www.sph.uth.tmc.edu/Retnet/), and a number
of small and large animal models that exist faithfully reca-
pitulate the human pathologies, allowing for the testing of
novel treatments.
Inherited retinal degenerations such as retinitis pigmen-
tosa (RP) or Leber Congenital Amaurosis (LCA) (Cremers,
van den Hurk, & den Hollander, 2002; Dryja, 2001; Kap-
lan, Perrault, & Unnich, 2000) are caused by mutations in
genes primarily expressed in photoreceptors or the retinal
pigment epithelium (RPE). RP and LCA are characterized
by extreme genotypic and phenotypic heterogeneity, vari-
ous patterns of Mendelian inheritance and primary and sec-
ondary cell involvement (Dryja, 2001; Kaplan et al., 2000).
Common retinal diseases inherited as complex traits are
age-related macular degeneration (AMD), proliferative dia-
betic retinopathy and retinopathy of prematurity (ROP),
which in their severe forms are characterized by ocular neo-
vascularization. The unbalance between pro- and anti-
angiogenetic molecules in favor of the former is the ﬁnal
common pathogenetic stimulus that triggers the formation
of aberrant vessels, eventually leading to blindness in ocular
neovascular diseases (Das & McGuire, 2003; Tuo, Boja-
nowski, & Chan, 2004). Finally, glaucoma is a common ret-
inal blinding disease characterized by increased intraocular
pressure which independently of its monogenic or multifac-
torial inheritance is associated with retinal ganglion cells
apoptosis (Sheﬃeld & Alward, 2000).
The typical approaches employed to correct retinal dis-
eases caused by recessive or dominant mutations are based
on gene replacement or gene inactivation, respectively
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rar, Kenna, & Humphries, 2002; Wilson & Wensel,
2003). In both cases the therapeutic nucleic acids need to
be targeted to the cells that are primarily aﬀected by the
mutation (i.e. the RPE or photoreceptors). In addition, a
generic strategy to delay retinal degeneration or the glau-
coma-associated retinal ganglion cell apoptosis has been
developed using gene delivery of secretable anti-apoptotic
factors or survival factors (Bainbridge, Tan, & Ali, 2006;
Borras, Brandt, Nickells, & Ritch, 2002; Surace & Auric-
chio, 2003). Viral-mediated gene delivery of secreted thera-
peutic proteins has additionally been used to provide
symptomatic treatments for those retinal diseases that are
characterized by ocular neovascularization. Animal models
of AMD and ROP have been successfully treated with
AAV vectors encoding for secretable anti-angiogenic mol-
ecules (Bainbridge et al., 2003; Campochiaro, 2007). The
use of soluble molecules in anti-angiogenic and neurotro-
phic therapy overcomes the problem of speciﬁcally target-
ing aﬀected cells, since the therapeutic protein produced
by ‘‘factory cells’’ can diﬀuse across the retina into ocular
ﬂuids (Auricchio, 2003).
Regardless of the retinal disease target and the therapeu-
tic strategy, aspects that are critical to the eﬃcacy of gene-
based therapies include: (i) route and timing of gene trans-
fer, (ii) eﬃciency and speciﬁcity of retinal cell transduction,
and (iii) transcriptional regulation of pattern, time and lev-
els of transgene expression.
2.1. Route and timing of gene transfer
The routes of vector administration to the retina deter-
mine which cells are exposed to the therapeutic agent.
The subretinal approach is typically used for treatment of
inherited retinal diseases aﬀecting photoreceptors or
RPE. The subretinal administration of AAV vectors results
in the transduction of both photoreceptors and RPE cells
(Surace & Auricchio, 2003). AAV vectors have been suc-
cessfully used to treat small and large animal models with
RPE-speciﬁc genetic defects including those causing muco-
polysaccharidosis VI (Ho et al., 2002) and VII (Hennig
et al., 2004), RP due to a MERTK deﬁciency (Smith
et al., 2003), LCA due to an RPE65 gene deﬁciency
(Acland et al., 2005; Acland et al., 2001; Dejneka et al.,
2004; Jacobson et al., 2006; LeMeur et al., 2007; Narfstrom
et al., 2003; Pang et al., 2006) and Ocular Albinism due to
OA1 deﬁciency (Surace et al., 2005). Gene transfer
approaches for correction of photoreceptor-speciﬁc dis-
eases with subretinal injection of AAV vectors were suc-
cessfully used to recover photoreceptor function in
murine models carrying null mutations for the rpgrip (Paw-
lyk et al., 2005) and rs1h genes (Min et al., 2005; Zeng
et al., 2004). Because the subretinal space is near to the
choroidal vascular plexus, subretinal administration of
AAV vectors encoding for anti-angiogenic factors was also
used to treat choroidal neovascularization (Lai et al., 2001;
Mori et al., 2002).The other route of vector administration is the intravi-
treal injection, which exposes the inner retina to the thera-
peutic agent. This route of administration was used to treat
optic neuritis in rodents (Guy, Qi, & Hauswirth, 1998; Qi,
Hauswirth, & Guy, 2007), to protect retinal ganglion cells
(RGC) in rat models of glaucoma (Martin & Quigley,
2004; McKinnon et al., 2002; Renwick et al., 2006; Zhou,
Pernet, Hauswirth, & Di Polo, 2005) and to treat models
of retinal neovascularization (Auricchio et al., 2002; Bain-
bridge et al., 2002; Lai et al., 2005; Raisler, Berns, Grant,
Beliaev, & Hauswirth, 2002).
An additional factor playing a critical role in viral-med-
iated retinal transduction is the time of gene delivery. Ret-
inal degeneration varies from early and severe to late and
progressive. Slowly progressive diseases have a much wider
therapeutic window than those with an earlier onset such as
LCA2. Timely gene delivery in early onset and congenital
retinal dystrophies may prevent the pathological conse-
quences of the mutation to retinal function. Administra-
tion of AAVs with reporter or therapeutic genes to the
fetal or the newborn murine retina results in robust trans-
gene expression and recovery of retinal pathology in both
models of retinal degeneration and neovascularization
(Auricchio et al., 2002; Bainbridge et al., 2002; Dejneka
et al., 2004; Lai et al., 2005; Raisler et al., 2002; Surace
et al., 2003).
2.2. Eﬃciency and speciﬁcity of retinal cell transduction
To be eﬀective, gene therapy to the retina initially
requires eﬃcient, speciﬁc and widely distributed transduc-
tion of virus to target cells. Once this is achieved, it is pos-
sible to tailor gene expression to appropriate levels and
spatial patterns through the use of speciﬁc promoter ele-
ments. Therefore, the main limiting step in the process is
the targeted transduction mediated by AAV. This includes:
vector binding to a speciﬁc receptor and entry into the tar-
get cell; intracellular traﬃcking to the nucleus; AAV
decapsidation and conversion of its single-strand genome
into a DNA duplex; transgene expression (Rabinowitz &
Samulski, 2000). The ﬁrst AAV serotype tested into the ret-
ina was AAV2/2 (Ali et al., 1996). The subretinal adminis-
tration of this serotype results in the transduction of both
photoreceptors and RPE cells, with an onset of transgene
expression that peaks at 4 weeks after vector administra-
tion (Ali et al., 1996; Auricchio et al., 2001; Bennett, Duan,
Engelhardt, & Maguire, 1997; Flannery et al., 1997; Rabi-
nowitz & Samulski, 2002; Rolling et al., 2000; Rolling
et al., 1999; Sarra et al., 2002). Intravitreal administration
of AAV2/2 results in transduction of ganglion cells, trabec-
ular meshwork cells and various cells of the inner nuclear
layer, including Mu¨ller cells (Ali et al., 1998; Auricchio
et al., 2001; Borras et al., 2006; Liang et al., 2001; Martin,
Klein, & Quigley, 2002). The availability of AAV vectors
derived from diﬀerent serotypes has enormously enhanced
AAV transduction eﬃciency and speciﬁcity (Auricchio
et al., 2001; Rabinowitz et al., 2002; Yang et al., 2002).
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or 2/4 vectors, robust expression of the EGFP reporter
gene is observed in the RPE of mice, dogs and non-human
primates (NHP) (Auricchio et al., 2001; Rabinowitz et al.,
2002; Weber et al., 2003; Yang et al., 2002). Subretinal
administration of AAV5/5 (where both genome and caps-
ids belong to AAV5) or AAV2/5 also results in early
RPE transduction, but more importantly, in robust expres-
sion in photoreceptors which is higher than that obtained
with AAV2/2. (Auricchio et al., 2001; Lotery et al., 2003;
Yang et al., 2002) (Fig. 2). Notably, intravitreal injection
of AAV2/1 and 2/5 resulted in poor transduction of the
inner retina (Auricchio et al., 2001). More recently large
numbers of novel AAV capsid sequences have been iso-
lated (see above) and some of these were used for the gen-
eration of novel AAV vectors, potentially allowing for
further expansion of AAV retinal tropism and transduction
(Fig. 1). Based on the ability of AAV2/7, 2/8, and 2/9 to
transduce various tissues (Cearley & Wolfe, 2006; Gao
et al., 2002; Inagaki et al., 2006; Pacak et al., 2006), we
recently tested their transduction characteristics in the mur-
ine retina. Subretinal delivery of AAV2/7 (Fig. 2), 2/8, or
2/9 (data not shown) vectors encoding EGFP, resulted in
eﬃcient transduction of both RPE and photoreceptor cells.
The ability of AAV2/7 and 2/8, as well as of AAV2/5 (to
date considered the best vector for photoreceptor transduc-
tion) to eﬃciently and rapidly transduce murine photore-
ceptors may have a signiﬁcant impact on developing
therapies for severe inherited photoreceptor diseases. To
this end, gene replacement with AAV2/2 vectors in the
rdl and rds murine models (due to deﬁciency in the pde6b
and peripherin genes, respectively) resulted in low levels
of photoreceptor transduction and in lack of rescue or in
short-lived rescue (Ali et al., 2000; Jomary, Vincent, Grist,
Neal, & Jones, 1997; Sarra et al., 2001; Schlichtenbrede
et al., 2003).
2.3. Transcriptional regulation of pattern, time and levels of
transgene expression
In inherited retinal diseases, stable expression of the
therapeutic gene is required at appropriate levels and
should be restricted to the cells in which the mutationFig. 2. Fluorescence microscopy analysis of EGFP expression four weeks post-
2/7-CMV-EGFP (central and right panel panels). The use of diﬀerent AAV vec
and cellular speciﬁcities. RPE, retinal pigment epithelium; ONL, outer nucleaexerts its detrimental eﬀect. Conversely, in diseases such
as retinal neovascularization, both levels and timing of
transgene expression should be regulated. Tissue-speciﬁc
promoters for RPE restricted gene expression include pro-
moter fragments from the RPE65, VMD2, and OA1 genes
(Acland et al., 2005; Dinculescu et al., 2005; Vetrini et al.,
2004). The proximal promoter region of the rod opsin
gene (RPPR) is used for photoreceptor-speciﬁc expression
(Flannery et al., 1997; Glushakova et al., 2006). As shown
in Fig. 2, subretinal administration of an AAV2/5 encod-
ing EGFP under the control of the ubiquitous CMV pro-
moter results in expression in both RPE and
photoreceptor cells, while the same AAV serotype harbor-
ing the RPPR promoter restricts EGFP expression to
photoreceptors.
Systems to regulate the timing and levels of gene expres-
sion have been developed to obtain therapeutic eﬃcacy and
avoid toxicity. For this purpose transcription factors have
been engineered that are regulated either positively or neg-
atively by small molecule drags (Clackson, 2000). Two
inducible systems have been tested in the murine and
NHP retina transduced with AAV vectors. One is based
on the ability of rapamycin to reconstitute a functional
transcription factor that binds to a promoter element
upstream of the target gene (Pollock et al., 2000; Rivera
et al., 1996). Subretinal administration of AAV containing
the regulated system followed by systemic administration
of rapamycin result in expression of the target gene that
is drug-dependent in time and levels (Auricchio, Rivera,
et al., 2002; Lebherz et al., 2005). Similar results have been
obtained using the tetracycline (tet)-inducibile system, in
which an activator or silencer (tetON or tetOFF, respec-
tively) vector and an inducible doxycycline (dox)-respon-
sive vector were subretinally injected in rats and NHP
(Dejneka et al., 2001; Folliot et al., 2003; McGee Sanftner,
Rendahl, & Quiroz, 2001; Smith et al., 2005; Stieger et al.,
2006).
In conclusion, the versatility, eﬃcacy and safety of AAV
vectors for retinal gene transfer have been successfully
determinate in animal models. AAV safety and eﬃcacy is
being tested in patients with LCA2 due to RPE65 muta-
tions (http://www.blindness.org; Bennett, 2006). This may
allow to treat many additional retinal diseases.subretinal injection of AAV2/5-RHO-EGFP (left panel) and AAV2/5- and
tor serotypes and promoters have distinct retinal transduction eﬃciencies
r layer; INL, inner nuclear layer; GCL, ganglion cell layer.
E.M. Surace, A. Auricchio / Vision Research 48 (2008) 353–359 357Acknowledgments
We thank Nadine S. Dejneka and Mariacarmela Allocca
for the critical reading of the manuscript. This work was
supported by the Telethon Grant TIGEM P21, the Milton
& Steinbach Fund, the EC-FP6-Projects LSHB-CT-2005-
512146 ‘‘DiMI’’ and 018933 ‘‘Clinigene’’, the National
Institutes of Health Grant 1R01EY015136-01 and the Ital-
ian Ministry of Agricolture Grant D.M.589/7303/04.References
Acland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A.
V., Bennicelli, J., et al. (2005). Long-term restoration of rod and cone
vision by single dose rAAV-mediated gene transfer to the retina in a
canine model of childhood blindness. Molecular Therapy, 12(6),
1072–1082.
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S.,
Cideciyan, A. V., et al. (2001). Gene therapy restores vision in a canine
model of childhood blindness. Nature Genetics, 28(1), 92–95.
Ali, R. R., Reichel, M. B., De Alwis, M., Kanuga, N., Kinnon, C.,
Levinsky, R. J., et al. (1998). Adeno-associated virus gene transfer to
mouse retina. Human Gene Therapy, 9(1), 81–86.
Ali, R. R., Reichel, M. B., Thrasher, A. J., Levinsky, R. J., Kinnon, C.,
Kanuga, N., et al. (1996). Gene transfer into the mouse retina
mediated by an adeno-associated viral vector. Human Molecular
Genetics, 5(5), 591–594.
Ali, R. R., Sarra, G. M., Stephens, C., Alwis, M. D., Bainbridge, J. W.,
Munro, P. M., et al. (2000). Restoration of photoreceptor ultrastruc-
ture and function in retinal degeneration slow mice by gene therapy.
Nature Genetics, 25(3), 306–310.
Allocca, M., Tessitore, A., Cotugno, G., & Auricchio, A. (2006). AAV-
mediated gene transfer for retinal diseases. Expert Opinion on
Biological Therapy, 6(12), 1279–1294.
Auricchio, A. (2003). Pseudotyped AAV vectors for constitutive and
regulated gene expression in the eye. Vision Research, 43(8), 913–918.
Auricchio, A., Behling, K., Maguire, A., O’Connor, E., Bennett, L.,
Wilson, J., et al. (2002). Inhibition of retinal neovascularization by
intraocular viral-mediated delivery of anti-angiogenic agents. Molec-
ular Therapy, 6(4), 490.
Auricchio, A., Kobinger, G., Anand, V., Hildinger, M., O’Connor, E.,
Maguire, A. M., et al. (2001). Exchange of surface proteins impacts on
viral vector cellular speciﬁcity and transduction characteristics: The
retina as a model. Human Molecular Genetics, 10(26), 3075–3081.
Auricchio, A., O’Connor, E., Weiner, D., Gao, G. P., Hildinger, M.,
Wang, L., et al. (2002). Noninvasive gene transfer to the lung for
systemic delivery of therapeutic proteins. The Journal of Clinical
Investigation, 110(4), 499–504.
Auricchio, A., Rivera, V., Clackson, T., O’Connor, E., Maguire, A.,
Tolentino, M., et al. (2002). Pharmacological regulation of protein
expression from adeno-associated viral vectors in the eye. Molecular
Therapy, 6(2), 238.
Auricchio, A., & Rolling, F. (2005). Adeno-associated viral vectors for
retinal gene transfer and treatment of retinal diseases. Current Gene
Therapy, 5(3), 339–348.
Bainbridge, J. W., Mistry, A., Binley, K., De Alwis, M., Thrasher, A. J.,
Naylor, S., et al. (2003). Hypoxia-regulated transgene expression in
experimental retinal and choroidal neovascularization. Gene Therapy,
10(12), 1049–1054.
Bainbridge, J. W., Mistry, A., De Alwis, M., Paleolog, E., Baker, A.,
Thrasher, A. J., et al. (2002). Inhibition of retinal neovascularisation
by gene transfer of soluble VEGF receptor sFlt-1. Gene Therapy, 9(5),
320–326.
Bainbridge, J. W., Tan, M. H., & Ali, R. R. (2006). Gene therapy progress
and prospects: The eye. Gene Therapy, 13(16), 1191–1197.Bennett, J. (2006). Commentary: An aye for eye gene therapy. Human
Gene Therapy, 17(2), 177–179.
Bennett, J., Duan, D., Engelhardt, J. F., & Maguire, A. M. (1997). Real-
time, noninvasive in vivo assessment of adeno-associated virus-
mediated retinal transduction. Investigative Ophthalmology & Visual
Science, 38(13), 2857–2863.
Bennett, J., & Maguire, A. M. (2000). Gene therapy for ocular disease.
Molecular Therapy, 1(6), 501–505.
Borras, T., Brandt, C. R., Nickells, R., & Ritch, R. (2002). Gene therapy
for glaucoma: Treating a multifaceted, chronic disease. Investigative
Ophthalmology & Visual Science, 43(8), 2513–2518.
Borras, T., Xue, W., Choi, V. W., Bartlett, J. S., Li, G., Samulski, R. J.,
et al. (2006). Mechanisms of AAV transduction in glaucoma-associ-
ated human trabecular meshwork cells. The Journal of Gene Medicine,
8(5), 589–602.
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P.,
Zolotukhin, S., et al. (2004). Recombinant AAV viral vectors
pseudotyped with viral capsids from serotypes 1, 2, and 5 display
diﬀerential eﬃciency and cell tropism after delivery to diﬀerent regions
of the central nervous system. Molecular Therapy, 10(2), 302–317.
Campochiaro, P. A. (2007). Gene therapy for ocular neovascularization.
Current Gene Therapy, 7(1), 25–33.
Cearley, C. N., & Wolfe, J. H. (2006). Transduction characteristics of
adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and
Rh10 in the mouse brain. Molecular Therapy, 13(3), 528–537.
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E.
(2000). Several log increase in therapeutic transgene delivery by
distinct adeno-associated viral serotype vectors. Molecular Therapy,
2(6), 619–623.
Chiorini, J. A., Kim, F., Yang, L., & Kotin, R. M. (1999). Cloning and
characterization of adeno-associated virus type 5. Journal of Virology,
73(2), 1309–1319.
Chiorini, J. A., Yang, L., Liu, Y., Safer, B., & Kotin, R. M. (1997).
Cloning of adeno-associated virus type 4 (AAV4) and generation of
recombinant AAV4 particles. Journal of Virology, 71(9), 6823–6833.
Clackson, T. (2000). Regulated gene expression systems. Gene Therapy,
7(2), 120–125.
Cremers, F. P., van den Hurk, J. A., & den Hollander, A. I. (2002).
Molecular genetics of Leber congenital amaurosis. Human Molecular
Genetics, 11(10), 1169–1176.
Das, A., & McGuire, P. G. (2003). Retinal and choroidal angiogenesis:
Pathophysiology and strategies for inhibition. Progress in Retinal and
Eye Research, 22(6), 721–748.
Dejneka, N. S., Auricchio, A., Maguire, A. M., Ye, X., Gao, G. P.,
Wilson, J. M., et al. (2001). Pharmacologically regulated gene expres-
sion in the retina following transduction with viral vectors. Gene
Therapy, 8(6), 442–446.
Dejneka, N. S., Surace, E. M., Aleman, T. S., Cideciyan, A. V.,
Lyubarsky, A., Savchenko, A., et al. (2004). In utero gene therapy
rescues vision in a murine model of congenital blindness. Molecular
Therapy, 9(2), 182–188.
Dinculescu, A., Glushakova, L., Min, S. H., & Hauswirth, W. W. (2005).
Adeno-associated virus-vectored gene therapy for retinal disease.
Human Gene Therapy, 16(6), 649–663.
Dryja, T. (2001). Retinitis pigmentosa and stationary night blindness. In
C. Scriver, A. Beaudet, W. Sly, & D. Valle (Eds.). The metabolic &
molecular bases of inherited diseases (Vol. IV, pp. 5903–5933). New
York, NY: McGraw-Hill.
Farrar, G. J., Kenna, P. F., & Humphries, P. (2002). On the genetics of
retinitis pigmentosa and on mutation-independent approaches to
therapeutic intervention. The EMBO Journal, 21(5), 857–864.
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M.,
Muzyczka, N., & Hauswirth, W. W. (1997). Eﬃcient photoreceptor-
targeted gene expression in vivo by recombinant adeno-associated
virus. Proceedings of the National Academy of Sciences of the United
States of America, 94(13), 6916–6921.
Folliot, S., Briot, D., Conrath, H., Provost, N., Cherel, Y., Moullier, P.,
et al. (2003). Sustained tetracycline-regulated transgene expression
358 E.M. Surace, A. Auricchio / Vision Research 48 (2008) 353–359in vivo in rat retinal ganglion cells using a single type 2 adeno-
associated viral vector. The Journal of Gene Medicine, 5(6), 493–501.
Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson,
J. M. (2002). Novel adeno-associated viruses from rhesus monkeys as
vectors for human gene therapy. Proceedings of the National Academy
of Sciences of the United States of America, 99(18), 11854–11859.
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou,
X., et al. (2004). Clades of adeno-associated viruses are widely
disseminated in human tissues. Journal of Virology, 78(12), 6381–6388.
Gao, G., Vandenberghe, L. H., & Wilson, J. M. (2005). New recombinant
serotypes of AAV vectors. Current Gene Therapy, 5(3), 285–297.
Glushakova, L. G., Timmers, A. M., Issa, T. M., Cortez, N. G., Pang, J.,
Teusner, J. T., et al. (2006). Does recombinant adeno-associated virus-
vectored proximal region of mouse rhodopsin promoter support only
rod-type speciﬁc expression in vivo? Molecular Vision, 12, 298–309.
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse,
L., Miller, D. G., et al. (2004). Systemic delivery of genes to striated
muscles using adeno-associated viral vectors. Nature Medicine, 10(8),
828–834.
Guy, J., Qi, X., & Hauswirth, W. W. (1998). Adeno-associated viral-
mediated catalase expression suppresses optic neuritis in experimental
allergic encephalomyelitis. Proceedings of the National Academy of
Sciences of the United States of America, 95(23), 13847–13852.
Halbert, C. L., Allen, J. M., & Miller, A. D. (2001). Adeno-associated
virus type 6 (AAV6) vectors mediate eﬃcient transduction of airway
epithelial cells in mouse lungs compared to that of AAV2 vectors.
Journal of Virology, 75(14), 6615–6624.
Hennig, A. K., Ogilvie, J. M., Ohlemiller, K. K., Timmers, A. M.,
Hauswirth, W. W., & Sands, M. S. (2004). AAV-mediated intravitreal
gene therapy reduces lysosomal storage in the retinal pigmented
epithelium and improves retinal function in adult MPS VII mice.
Molecular Therapy, 10(1), 106–116.
Hermonat, P. L., & Muzyczka, N. (1984). Use of adeno-associated vims as
a mammalian DNA cloning vector: Transduction of neomycin
resistance into mammalian tissue culture cells. Proceedings of the
National Academy of Sciences of the United States of America, 81(20),
6466–6470.
Hildinger, M., Auricchio, A., Gao, G., Wang, L., Chirmule, N., & Wilson,
J. M. (2001). Hybrid vectors based on adeno-associated virus serotypes
2 and 5 for muscle-directed gene transfer. Journal of Virology, 75(13),
6199–6203.
Ho, T. T., Maguire, A. M., Aguirre, G. D., Surace, E. M., Anand, V.,
Zeng, Y., et al. (2002). Phenotypic rescue after adeno-associated virus-
mediated delivery of 4-sulfatase to the retinal pigment epithelium of
feline mucopolysaccharidosis VI. The Journal of Gene Medicine, 4(6),
613–621.
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., McTiernan, C. F.,
Kay, M. A., et al. (2006). Robust systemic transduction with AAV9
vectors in mice: Eﬃcient global cardiac gene transfer superior to that
of AAV8. Molecular Therapy, 14(1), 45–53.
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz,
S. B., Cideciyan, A. V., et al. (2006). Safety of recombinant adeno-
associated virus type 2-RPE65 vector delivered by ocular subretinal
injection. Molecular Therapy, 31(6), 1074–1084.
Jomary, C., Vincent, K. A., Grist, J., Neal, M. J., & Jones, S. E. (1997).
Rescue of photoreceptor function by AAV-mediated gene transfer in a
mouse model of inherited retinal degeneration. Gene Therapy, 4(7),
683–690.
Kaplan, J., Perrault, R. J., & Unnich, A. (2000). Leber congenital
amaurosis. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. M. Valle
(Eds.). The metabolic and molecular bases of inherited disease (Vol. 4,
pp. 5945–5947). New york, NY: McGraw-Hill.
Lai, C. M., Shen, W. Y., Brankov, M., Lai, Y. K., Barnett, N. L., Lee, S.
Y., et al. (2005). Long-term evaluation of AAV-mediated sFlt-1 gene
therapy for ocular neovascularization in mice and monkeys.Molecular
Therapy, 12(4), 659–668.
Lai, C. C., Wu, W. C., Chen, S. L., Xiao, X., Tsai, T. C., Huan, S. J.,
et al. (2001). Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Investigative Ophthal-
mology & Visual Science, 42(10), 2401–2407.
Lebherz, C., Auricchio, A., Maguire, A. M., Rivera, V. M., Tang, W.,
Grant, R. L., et al. (2005). Long-term inducible gene expression in the
eye via adeno-associated virus gene transfer in nonhuman primates.
Human Gene Therapy, 16(2), 178–186.
LeMeur, G., Stieger, K., Smith, A. J., Weber, M., Deschamps, J. Y.,
Nivard, D., et al. (2007). Restoration of vision in RPE65-deﬁcient
Briard dogs using an AAV serotype 4 vector that speciﬁcally
targets the retinal pigmented epithelium. Gene Therapy, 14(4),
292–303.
Liang, F. Q., Aleman, T. S., Dejneka, N. S., Dudus, L., Fisher, K. J.,
Maguire, A. M., et al. (2001). Long-term protection of retinal
structure but not function using RAAV.CNTF in animal models of
retinitis pigmentosa. Molecular Therapy, 4(5), 461–472.
Limberis, M. P., & Wilson, J. M. (2006). Adeno-associated virus serotype
9 vectors transduce murine alveolar and nasal epithelia and can be
readministered. Proceedings of the National Academy of Sciences of the
United States of America, 103(35), 12993–12998.
Liu, G., Martins, I. H., Chiorini, J. A., & Davidson, B. L. (2005). Adeno-
associated virus type 4 (AAV4) targets ependyma and astrocytes in the
subventricular zone and RMS. Gene Therapy, 12(20), 1503–1508.
Lotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M.,
Stone, E. M., et al. (2003). Adeno-associated virus type 5: Transduc-
tion eﬃciency and cell-type speciﬁcity in the primate retina. Human
Gene Therapy, 14(17), 1663–1671.
Martin, K. R., Klein, R. L., & Quigley, H. A. (2002). Gene delivery to the
eye using adeno-associated viral vectors. Methods, 28(2), 267–275.
Martin, K. R., & Quigley, H. A. (2004). Gene therapy for optic nerve
disease. Eye, 18(11), 1049–1055.
Mastakov, M. Y., Baer, K., Kotin, R. M., & During, M. J. (2002).
Recombinant adeno-associated virus serotypes 2- and 5-mediated gene
transfer in the mammalian brain: Quantitative analysis of heparin co-
infusion. Molecular Therapy, 5(4), 371–380.
McGee Sanftner, L. H., Rendahl, K. G., & Quiroz, D. (2001).
Recombinant AAV-mediated delivery of a tet-inducible reporter gene
to the rat retina. Molecular Therapy, 3(5 Pt 1), 688–696.
McKinnon, S. J., Lehman, D. M., Tahzib, N. G., Ransom, N. L.,
Reitsamer, H. A., Liston, P., et al. (2002). Baculoviral IAP repeat-
containing-4 protects optic nerve axons in a rat glaucoma model.
Molecular Therapy, 5(6), 780–787.
Min, S. H., Molday, L. L., Seeliger, M. W., Dinculescu, A., Timmers, A.
M., Janssen, A., et al. (2005). Prolonged recovery of retinal structure/
function after gene therapy in an Rs1h-deﬁcient mouse model of x-
linked juvenile retinoschisis. Molecular Therapy, 12(4), 644–651.
Mori, K., Gehlbach, P., Yamamoto, S., Duh, E., Zack, D. J., Li, Q., et al.
(2002). AAV-mediated gene transfer of pigment epithelium-derived
factor inhibits choroidal neovascularization. Investigative Ophthalmol-
ogy & Visual Science, 43(6), 1994–2000.
Muzyczka, N. (2001). Parvoviridae: The viruses and their replication.
Fundamental virology. Philadelphia: Lippincott Williams & Wilkins,
pp. 2327–2359.
Narfstrom, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A.,
Redmond, T. M., et al. (2003). Functional and structural recovery of
the retina after gene therapy in the RPE65 null mutation dog.
Investigative Ophthalmology & Visual Science, 44(4), 1663–1672.
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A.,
Cloutier, D. E., et al. (2006). Recombinant adeno-associated virus
serotype 9 leads to preferential cardiac transduction in vivo. Circula-
tion Research, 99(4), e3–e9.
Pang, J. J., Chang, B., Kumar, A., Nusinowitz, S., Noorwez, S. M., Li, J.,
et al. (2006). Gene therapy restores vision-dependent behavior as well
as retinal structure and function in a mouse model of RPE65 Leber
congenital amaurosis. Molecular Therapy, 13(3), 565–572.
Passini, M. A., Watson, D. J., Vite, C. H., Landsburg, D. J., Feigenbaum,
A. L., & Wolfe, J. H. (2003). Intraventricular brain injection of adeno-
associated virus type 1 (AAV1) in neonatal mice results in
complementary patterns of neuronal transduction to AAV2 and total
E.M. Surace, A. Auricchio / Vision Research 48 (2008) 353–359 359long-term correction of storage lesions in the brains of beta-glucuron-
idase-deﬁcient mice. Journal of Virology, 77(12), 7034–7040.
Pawlyk, B. S., Smith, A. J., Buch, P. K., Adamian, M., Hong, D. H.,
Sandberg, M. A., et al. (2005). Gene replacement therapy rescues
photoreceptor degeneration in a murine model of Leber congenital
amaurosis lacking RPGRIP. Investigative Ophthalmology & Visual
Science, 46(9), 3039–3045.
Pollock, R., Issner, R., Zoller, K., Natesan, S., Rivera, V. M., & Clackson,
T. (2000). Delivery of a stringent dimerizer-regulated gene expression
system in a single retroviral vector. Proceedings of the National
Academy of Sciences of the United States of America, 97(24),
13221–13226.
Qi, X., Hauswirth, W. W., & Guy, J. (2007). Dual gene therapy with
extracellular superoxide dismutase and catalase attenuates experimen-
tal optic neuritis. Molecular Vision, 13, 1–11.
Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X.,
et al. (2002). Cross-packaging of a single adeno-associated virus
(AAV) type 2 vector genome into multiple AAV serotypes enables
transduction with broad speciﬁcity. Journal of Virology, 76(2),
791–801.
Rabinowitz, J. E., & Samulski, RJ. (2000). Building a better vector: The
manipulation of AAV virions. Virology, 278(2), 301–308.
Rabinowitz, J. E., & Samulski, R. J. (2002). The adeno-associated virus
crystal: Impact inversely proportional to size.Molecular Therapy, 6(4),
443–445.
Raisler, B. J., Berns, K. I., Grant, M. B., Beliaev, D., & Hauswirth, W. W.
(2002). Adeno-associated virus type-2 expression of pigmented epithe-
lium-derived factor or Kringles 1–3 of angiostatin reduce retinal
neovascularization. Proceedings of the National Academy of Sciences of
the United States of America, 99(13), 8909–8914.
Renwick, J., Narang, M. A., Coupland, S. G., Xuan, J. Y., Baker, A. N.,
Brousseau, J., et al. (2006). XIAP-mediated neuroprotection in retinal
ischemia. Gene Therapy, 13(4), 339–347.
Rivera, V. M., Clackson, T., Natesan, S., Pollock, R., Amara, J. F.,
Keenan, T., et al. (1996). A humanized system for pharmacologic
control of gene expression. Nature Medicine, 2(9), 1028–1032.
Rolling, F., Shen, W. Y., Barnett, N. L., Tabarias, H., Kanagasingam, Y.,
Constable, I., et al. (2000). Long-term real-time monitoring of adeno-
associated virus-mediated gene expression in the rat retina. Clinical and
Experimental Ophthalmology, 28(5), 382–386.
Rolling, F., Shen, W. Y., Tabarias, H., Constable, I., Kanagasingam, Y.,
Barry, C. J., et al. (1999). Evaluation of adeno-associated virus-
mediated gene transfer into the rat retina by clinical ﬂuorescence
photography. Human Gene Therapy, 10(4), 641–648.
Rutledge, E. A., Halbert, C. L., & Russell, D. W. (1998). Infectious clones
and vectors derived from adeno-associated virus (AAV) serotypes
other than AAV type 2. Journal of Virology, 72(1), 309–319.
Sarra, G. M., Stephens, C., de Alwis, M., Bainbridge, J. W., Smith, A. J.,
Thrasher, A. J., et al. (2001). Gene replacement therapy in the retinal
degeneration slow (rds) mouse: The eﬀect on retinal degeneration
following partial transduction of the retina. Human Molecular Genet-
ics, 10(21), 2353–2361.
Sarra, G. M., Stephens, C., Schlichtenbrede, F. C., Bainbridge, J. W.,
Thrasher, A. J., Luthert, P. J., et al. (2002). Kinetics of transgene
expression in mouse retina following sub-retinal injection of
recombinant adeno-associated virus. Vision Research, 42(4),
541–549.
Schlichtenbrede, F. C., da Cruz, L., Stephens, C., Smith, A. J.,
Georgiadis, A., Thrasher, A. J., et al. (2003). Long-term evaluation
of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated
gene replacement therapy. The Journal of Gene Medicine, 5(9),
757–764.
Sheﬃeld, V. C. W., & Alward, L. M. (2000). The glaucomas. The
metabolic and molecular bases of inherited disease (Vol. IV,
pp. 6063–6093). New York, St. Louis, San Francisco: McGraw-Hill.
Smith, A. J., Schlichtenbrede, F. C., Tschernutter, M., Bainbridge, J. W.,
Thrasher, A. J., & Ali, R. R. (2003). AAV-mediated gene transferslows photoreceptor loss in the RCS rat model of retinitis pigmentosa.
Molecular Therapy, 8(2), 188–195.
Smith, J. R., Verwaerde, C., Rolling, F., Naud, M. C., Delanoye, A.,
Thillaye-Goldenberg, B., et al. (2005). Tetracycline-inducible viral
interleukin-10 intraocular gene transfer, using adeno-associated virus
in experimental autoimmune uveoretinitis. Human Gene Therapy,
16(9), 1037–1046.
Stieger, K., Le Meur, G., Lasne, F., Weber, M., Deschamps, J. Y., Nivard,
D., et al. (2006). Long-term doxycycline-regulated transgene expres-
sion in the retina of nonhuman primates following subretinal injection
of recombinant AAV vectors. Molecular Therapy, 13(5), 967–975.
Surace, E. M., & Auricchio, A. (2003). Adeno-associated viral vectors for
retinal gene transfer. Progress in Retinal and Eye Research, 22(6),
705–719.
Surace, E. M., Auricchio, A., Reich, S. J., Rex, T., Glover, E., Pineles, S.,
et al. (2003). Delivery of adeno-associated virus vectors to the fetal
retina: Impact of viral capsid proteins on retinal neuronal progenitor
transduction. Journal of Virology, 77(14), 7957–7963.
Surace, E. M., Domenici, L., Cortese, K., Cotugno, G., Di Vicino, U.,
Venturi, C., et al. (2005). Amelioration of both functional and
morphological abnormalities in the retina of a mouse model of ocular
albinism following AAV-mediated gene transfer. Molecular Therapy,
12(4), 652–658.
Tratschin, J. D., West, M. H., Sandbank, T., & Carter, BJ. (1984). A
human parvovirus, adeno-associated virus, as a eucaryotic vector:
Transient expression and encapsidation of the procaryotic gene for
chloramphenicol acetyltransferase. Molecular and Cellular Biology,
4(10), 2072–2081.
Tuo, J., Bojanowski, CM., & Chan, C. C. (2004). Genetic factors of age-
related macular degeneration. Progress in Retinal and Eye Research,
23(2), 229–249.
Vetrini, F., Auricchio, A., Du, J., Angeletti, B., Fisher, D. E., Ballabio, A.,
et al. (2004). The microphthalmia transcription factor (Mitf) controls
expression of the ocular albinism type 1 gene: Link between melanin
synthesis and melanosome biogenesis. Molecular and Cellular Biology,
24(15), 6550–6559.
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., et al. (2005).
Adeno-associated virus serotype 8 eﬃciently delivers genes to muscle
and heart. Nature Biotechnology, 23(3), 321–328.
Weber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot,
D., et al. (2003). Recombinant adeno-associated virus serotype 4
mediates unique and exclusive long-term transduction of retinal
pigmented epithelium in rat, dog, and nonhuman primate after
subretinal delivery. Molecular Therapy, 7(6), 774–781.
Wilson, J. H., & Wensel, T. G. (2003). The nature of dominant mutations
of rhodopsin and implications for gene therapy. Molecular Neurobi-
ology, 28(2), 149–158.
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson,
J. M. (1999). Gene therapy vectors based on adeno-associated virus
type 1. Journal of Virology, 73(5), 3994–4003.
Yang, G. S., Schmidt, M., Yan, Z., Lindbloom, J. D., Harding, T. C.,
Donahue, B. A., et al. (2002). Virus-mediated transduction of murine
retina with adeno-associated virus: Eﬀects of viral capsid and genome
size. Journal of Virology, 76(15), 7651–7660.
Zabner, J., Seiler, M., Walters, R., Kotin, R. M., Fulgeras, W., Davidson,
B. L., et al. (2000). Adeno-associated virus type 5 (AAV5) but not
AAV2 binds to the apical surfaces of airway epithelia and facilitates
gene transfer. Journal of Virology, 74(8), 3852–3858.
Zeng, Y., Takada, Y., Kjellstrom, S., Hiriyanna, K., Tanikawa, A.,
Wawrousek, E., et al. (2004). RS-1 gene delivery to an adult Rslh
knockout mouse model restores ERG b-wave with reversal of the
electronegative waveform of X-linked retinoschisis. Investigative Oph-
thalmology & Visual Science, 45(9), 3279–3285.
Zhou, Y., Pernet, V., Hauswirth, W. W., & Di Polo, A. (2005). Activation
of the extracellular signal-regulated kinase 1/2 pathway by AAV gene
transfer protects retinal ganglion cells in glaucoma. Molecular Ther-
apy, 12(3), 402–412.
